{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:39:46Z","timestamp":1793990386213,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019507","name":"Ortho Dermatologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s13555-022-00746-6","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T20:05:01Z","timestamp":1654632301000},"page":"1289-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-0007","authenticated-orcid":false,"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"746_CR1","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9:504\u201313.","journal-title":"Am Health Drug Benefits"},{"key":"746_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000484520","volume":"233","author":"GS Naik","year":"2017","unstructured":"Naik GS, Ming WK, Magodoro IM, et al. Th17 inhibitors in active psoriatic arthritis: a systematic review and meta-analysis of randomized controlled clinical trials. Dermatology. 2017;233:366\u201377.","journal-title":"Dermatology"},{"key":"746_CR3","first-page":"189","volume":"10","author":"LM Aldredge","year":"2018","unstructured":"Aldredge LM, Higham RC. Manifestations and management of difficult-to-treat psoriasis. J Dermatol Nurces Assoc. 2018;10:189\u201397.","journal-title":"J Dermatol Nurces Assoc"},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/14656566.2018.1448788","volume":"19","author":"D Kivelevitch","year":"2018","unstructured":"Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. 2018;19:561\u201375.","journal-title":"Expert Opin Pharmacother"},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000504841","volume":"237","author":"K Callis Duffin","year":"2021","unstructured":"Callis Duffin K, Mason MA, Gordon K, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. Dermatology. 2021;237:46\u201355.","journal-title":"Dermatology"},{"key":"746_CR6","volume-title":"Koebner phenomenon","author":"DP Sanchez","year":"2022","unstructured":"Sanchez DP, Sonthalia S. Koebner phenomenon. Treasure Island: StatPearls; 2022."},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3.","journal-title":"BMC Dermatol"},{"key":"746_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31: e12589.","journal-title":"Dermatol Ther"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bjd.17689","volume":"181","author":"KF Hjuler","year":"2019","unstructured":"Hjuler KF, Iversen L, Rasmussen MK, Kofoed K, Skov L, Zachariae C. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181:332\u20137.","journal-title":"Br J Dermatol"},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","volume":"74","author":"P Rich","year":"2016","unstructured":"Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","volume":"10","author":"N Wasel","year":"2020","unstructured":"Wasel N, Thaci D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10:663\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2340\/00015555-3098","volume":"99","author":"F Bardazzi","year":"2019","unstructured":"Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99:516\u201323.","journal-title":"Acta Derm Venereol"},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156:258\u201369.","journal-title":"JAMA Dermatol"},{"key":"746_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277-86.e210.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR15","unstructured":"HUMIRA [package insert]. North Chicago: AbbVie Inc; 2021."},{"key":"746_CR16","unstructured":"COSENTYX [package insert]. East Hanover: Novartis Pharmaceuticals Corporation; 2020."},{"key":"746_CR17","unstructured":"TREMFYA [package insert]. Horsham: Janssen Biotech, Inc; 2020."},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/jdv.16181","volume":"34","author":"JF Merola","year":"2020","unstructured":"Merola JF, Ghislain PD, Dauendorffer JN, et al. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. J Eur Acad Dermatol Venereol. 2020;34:1257\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-020-00411-w","volume":"10","author":"A Menter","year":"2020","unstructured":"Menter A, Armstrong A, Van Voorhees A, Liu C, Jacobson A. Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics. Dermatol Ther (Heidelb). 2020;10:615\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"746_CR20","unstructured":"SILIQ [package insert]. Bridgewater: Bausch Health US, LLC; 2017."},{"key":"746_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/09546634.2018.1427205","volume":"29","author":"L Sawyer","year":"2018","unstructured":"Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen MA. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat. 2018;29:557\u201368.","journal-title":"J Dermatolog Treat"},{"key":"746_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.36849\/JDD.2020.4645","volume":"19","author":"L Green","year":"2020","unstructured":"Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A. Clinical and molecular effects of interleukin-17 pathway blockade in psoriasis. J Drugs Dermatol. 2020;19:138\u201343.","journal-title":"J Drugs Dermatol"},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/CCID.S211938","volume":"12","author":"A Pinter","year":"2019","unstructured":"Pinter A, Bonnekoh B, Hadshiew IM, Zimmer S. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509\u201317.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"746_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"33","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Cornic L, Levin L\u00c5, Gibbons C, M\u00f8ller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33:355\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5499\/wjr.v3.i3.25","volume":"3","author":"K Boniface","year":"2013","unstructured":"Boniface K, Moynet D, Mossalayi MD. Role of Th17 cells in the pathogenesis of rheumatoid arthritis. World J Rheumatol. 2013;3:25\u201331.","journal-title":"World J Rheumatol"},{"key":"746_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763\u201376.","journal-title":"Nat Rev Drug Discov"},{"key":"746_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jaad.2019.05.094","volume":"82","author":"J Bagel","year":"2020","unstructured":"Bagel J, Lebwohl M, Israel RJ, Jacobson A. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020;82:344\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","volume":"151","author":"JJ Crowley","year":"2015","unstructured":"Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS, National Psoriasis Foundation. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151:87\u201394.","journal-title":"JAMA Dermatol"},{"key":"746_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/reum.2017.68912","volume":"55","author":"P Sobolewski","year":"2017","unstructured":"Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55:131\u20135.","journal-title":"Reumatologia"},{"key":"746_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","volume":"49","author":"P Rich","year":"2003","unstructured":"Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000507298","volume":"6","author":"D Rigopoulos","year":"2020","unstructured":"Rigopoulos D, Stathopoulou A, Gregoriou S. Small molecules and biologics in the treatment of nail psoriasis. Skin Appendage Disord. 2020;6:134\u201341.","journal-title":"Skin Appendage Disord"},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","volume":"11","author":"E Hadeler","year":"2021","unstructured":"Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail psoriasis: a review of effective therapies and recommendations for management. Dermatol Ther (Heidelb). 2021;11:799\u2013831.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"746_CR33","first-page":"adv00318","volume":"100","author":"J Szeb\u00e9nyi","year":"2020","unstructured":"Szeb\u00e9nyi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12\/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis. Acta Derm Venereol. 2020;100:adv00318.","journal-title":"Acta Derm Venereol"},{"key":"746_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ced.14314","volume":"46","author":"L Thomas","year":"2021","unstructured":"Thomas L, Azad J, Takwale A. Management of nail psoriasis. Clin Exp Dermatol. 2021;46:3\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"6 suppl 1","key":"746_CR35","first-page":"S12","volume":"9","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9(6 suppl 1):S12\u20136.","journal-title":"J Clin Aesthet Dermatol"},{"key":"746_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","volume":"33","author":"B Elewski","year":"2022","unstructured":"Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2022;33:261\u20135.","journal-title":"J Dermatolog Treat"},{"key":"746_CR37","first-page":"e299","volume":"35","author":"S Gregoriou","year":"2021","unstructured":"Gregoriou S, Tsiogka A, Tsimpidakis A, Nicolaidou E, Kontochristopoulos G, Rigopoulos D. Treatment of nail psoriasis with brodalumab: an open-label unblinded study. J Eur Acad Dermatol Venereol. 2021;35:e299\u2013301.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"746_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44\u201352.","journal-title":"J Dermatol Sci"},{"key":"746_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A, Szyma\u0144ska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56:392\u20138.","journal-title":"Reumatologia"},{"key":"746_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2020","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21:355\u201370.","journal-title":"Am J Clin Dermatol"},{"key":"746_CR41","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2014.04.063","volume":"71","author":"J Chung","year":"2014","unstructured":"Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","volume":"35","author":"B Engin","year":"2017","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19\u201327.","journal-title":"Clin Dermatol"},{"key":"746_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98:13\u20139.","journal-title":"J Dermatol Sci"},{"key":"746_CR44","volume-title":"Palmoplantar psoriasis","author":"A Miceli","year":"2021","unstructured":"Miceli A, Schmieder GJ. Palmoplantar psoriasis. Treasure Island: StatPearls; 2021."},{"key":"746_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jdv.14647","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Haydey R, Rosoph LA, et al. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol. 2018;32:403\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6 suppl","key":"746_CR46","doi-asserted-by":"publisher","first-page":"AB214","DOI":"10.1016\/j.jaad.2020.06.946","volume":"83","author":"M Politou","year":"2020","unstructured":"Politou M, Pompou M, Afroditi KI, Giannoukos A, Nikolaos F. Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab. J Am Acad Dermatol. 2020;83(6 suppl):AB214.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR47","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/bjd.12223","volume":"168","author":"AM Brunasso","year":"2013","unstructured":"Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168:1243\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"746_CR48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","volume":"11","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021;11(3):769\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"746_CR49","first-page":"45","volume":"10","author":"E Mah\u00e9","year":"2020","unstructured":"Mah\u00e9 E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis (Auckl). 2020;10:45\u201356.","journal-title":"Psoriasis (Auckl)"},{"key":"746_CR50","first-page":"33","volume":"6","author":"K Blakely","year":"2016","unstructured":"Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33\u201340.","journal-title":"Psoriasis (Auckl)"},{"key":"746_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjd.12663","volume":"170","author":"J Schmitt","year":"2014","unstructured":"Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170:274\u2013303.","journal-title":"Br J Dermatol"},{"key":"746_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421\u20134.","journal-title":"Arch Dermatol Res"},{"key":"746_CR54","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjd.17318","volume":"180","author":"RG Langley","year":"2019","unstructured":"Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019;180:306\u201314.","journal-title":"Br J Dermatol"},{"key":"746_CR55","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","volume":"84","author":"J Yeung","year":"2021","unstructured":"Yeung J, Vender R, Turchin I, et al. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. J Am Acad Dermatol. 2021;84:1169\u201371.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","volume":"81","author":"G Kimmel","year":"2019","unstructured":"Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"746_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","volume":"72","author":"K Papp","year":"2015","unstructured":"Papp K, Menter A, Strober B, et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2015;72(3):436-9.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6 suppl","key":"746_CR58","doi-asserted-by":"publisher","first-page":"AB181","DOI":"10.1016\/j.jaad.2020.06.811","volume":"83","author":"A Armstrong","year":"2020","unstructured":"Armstrong A, Strober B, Drew S, Cronin A, Jacobson A. Real-world characteristics of patients with psoriasis initiating brodalumab: findings from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2020;83(6 suppl):AB181.","journal-title":"J Am Acad Dermatol"},{"key":"746_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdv.16931","volume":"35","author":"MC Fargnoli","year":"2021","unstructured":"Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35:693\u2013700.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"746_CR60","first-page":"1","volume":"23","author":"S Rusta-Sallehy","year":"2018","unstructured":"Rusta-Sallehy S, Gooderham M, Papp K. Brodalumab: a review of safety. Skin Therapy Lett. 2018;23:1\u20133.","journal-title":"Skin Therapy Lett"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00746-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T04:25:05Z","timestamp":1655785505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00746-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}